XML 45 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
License and Collaboration Agreements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Feb. 12, 2024
Jul. 23, 2017
Apr. 30, 2018
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue, excluding assessed tax       $ 21,639,000 $ 21,594,000  
Non-cash royalty revenue related to the sales of future royalties            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue, excluding assessed tax       15,508,000 $ 16,861,000  
Bristol Myers Squibb Company            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Sale of stock shares repurchased 8,300,000          
Sale of stock repurchased cash consideration $ 3,000,000          
Bristol Myers Squibb Company | Purchase Agreement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Shares issued (in shares)     8,284,600      
Sale of stock consideration received     $ 850,000,000      
Other Partner            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Potential future additional payments for development milestones       $ 40,000,000    
Nektar-358 | Eli Lilly            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Percentage of sharing in Phase 2 development costs   75.00%        
Nektar-358 | Maximum | Eli Lilly And Company            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Potential future additional development and regulatory milestones (up to)   $ 250,000,000        
Bristol Myers Squibb Collaboration Agreement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Sale of stock shares repurchased 8,300,000          
Sale of stock repurchased cash consideration $ 3,000,000          
Nektar's | Nektar-358            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Received upfront and milestone payment   $ 150,000,000        
Percentage of sharing in Phase 2 development costs   25.00%        
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront and milestone payments received from license agreements     $ 1,000,000,000      
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Milestone One            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Potential future additional payments for development milestones           $ 50,000,000